INmune Bio sets Q3 2025 results call for Oct 30 at 4:30 ET

INmune Bio (INMB) will host a conference call on October 30, 2025 at 4:30 p.m. Eastern Time to discuss results for its third quarter ended September 30, 2025 and provide a corporate update.

Rhea-AI Filing Summary

INmune Bio (INMB) will host a conference call on October 30, 2025 at 4:30 p.m. Eastern Time to discuss results for its third quarter ended September 30, 2025 and provide a corporate update. The company attached a related press release as Exhibit 99.1.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did INMB announce in this 8-K?

INmune Bio announced it will host a conference call on October 30, 2025 at 4:30 p.m. ET to discuss Q3 results and provide a corporate update.

Which period will INMB discuss on the call?

Results for its third quarter ended September 30, 2025.

When is the INMB Q3 2025 conference call?

The call is scheduled for October 30, 2025 at 4:30 p.m. Eastern Time.

What additional materials did INMB provide?

A press release dated October 23, 2025 was furnished as Exhibit 99.1.

What topics will the INMB call cover?

Third-quarter 2025 results and a corporate update.

What is INMB’s trading symbol and exchange?

INmune Bio’s common stock trades under INMB on The NASDAQ Stock Market LLC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/28/2025 - 04:01 PM Learn about SEC filing dates

false 0001711754 0001711754 2025-10-23 2025-10-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 23, 2025

INMUNE BIO INC.

(Exact name of registrant as specified in charter)

Nevada		001-38793		47-5205835
(State or other jurisdiction		(Commission File Number)		(IRS Employer
of incorporation)				Identification No.)

225 NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432

(Address of Principal Executive Offices) (Zip Code)

(561) 710-0512 

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per shares		INMB		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On October 23, 2025, INmune Bio Inc. issued a press release announcing that it will host a conference call on Thursday, October 30, 2025, at 4:30 p.m., Eastern Time to discuss results for its third quarter ended September 30, 2025, and to provide a corporate update. A copy of the press release is attached herewith as Exhibit 99.1.

A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial statements and Exhibits

(d) Exhibits.

99.1		Press Release, dated October 23, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	INMUNE BIO INC.
Date: October 28, 2025	By:	/s/ David Moss
		David Moss
		Chief Executive Officer

2